CareDx Reports Q2 2025 Earnings with Revenue Growth and Policy Concerns
CareDx (CDNA) reported Q2 2025 earnings with adjusted revenue of $90.5 million, up 14% year-over-year. The company expressed concerns over potential reimbursement changes that could create a $15 million to $30 million annual financial headwind. Testing services volume grew by 13% sequentially, with kidney testing showing nearly 20% year-over-year growth.
Tickers: $CDNA
Topics: AlloMap Heart financial impact regulatory changes revenue growth testing services